Back to Charting the path to the next normal

Vaccine development and the two-hour marathon

The mean development timeline for all new drugs (including vaccines) since 2000—from clinical testing to approval—was about ten years. Yet three COVID-19 vaccines were granted emergency-use authorization (EUA) or other forms of approval in Europe, the United Kingdom, or the United States just 11 months after the SARS-CoV-2 sequence was published. At every step, science moved faster than anyone thought possible—just like modern marathoners.

Development times for COVID-19 vaccines were highly compressed compared with standard practice.
We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@mckinsey.com

To read the article, see “Fast-forward: Will the speed of COVID-19 vaccine development reset industry norms?”, May 13, 2021.